[Etiopathogenesis and therapeutic trends in adult T-cell leukemia associated with HTLV-I retrovirus].
HTLV-I (Human T-cell leukemia virus type I) has been the first human retrovirus identified and then associated with a definite pathological entity, a leukemic syndrome that specifically affects mature T-lymphocytes (ATL, adult T-cell leukemia), expressing CD3+, CD4+, CD8-, CD11- phenotype. This form of leukemia/lymphoma is endemic in southwestern islands of Japan, although at present the number of HTLV-I seropositive individuals has greatly increased, with a worldwide diffusion, following the expansion wave of the AIDS-associated HIV retrovirus. In fact, double seropositivity for both HIV and HTLV is frequently found among intravenous drug users. Although ATL leukemia or lymphoma occurs with a low frequency among HTLV-I seropositive individuals, it is likely that the evolution from a latent phase of infection to acute leukemia could be favoured by depression of immunosurveillance levels in the host. Therefore, special attention is required to prevent the diffusion of this retrovirus in adults, taking into consideration that newborn babies from seropositive mothers have to be considered at high risk for development of HTLV-I associated disease, on the basis of their immature immunocompetence.
D'Onofrio
C
C
Dipartimento di Medicina Sperimentale e Scienze Biochimiche, II Università degli Studi di Roma Tor Vergata.
Bonmassar
E
E
D000328:Adult; D002648:Child; D011464:Epoprostenol / Q000627:therapeutic use; D005260:Female; D015490:HTLV-I Infections / Q000276:immunology / Q000517:prevention & control; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000276:immunology; D006801:Humans; D007231:Infant, Newborn; D007372:Interferons / Q000627:therapeutic use; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000209:etiology / Q000628:therapy; D008297:Male; D011454:Prostaglandins A / Q000627:therapeutic use
D011454:Prostaglandins A; D007372:Interferons; D011464:Epoprostenol